CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / NUVL (NUVL) / alectinib
Forward catalyst · NUVL

alectinib

Sponsor NUVL · listed as NUVL

READOUT Phase 2;Phase 3 Confidence: medium Source: clinicaltrials

alectinib is a clinical-stage drug asset sponsored by NUVL, listed as NUVL. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Oct 31, 2026 (day precision, medium confidence), tied to trial NCT03178552. The asset is in Phase 2;Phase 3 and currently active not recruiting, studied in Non-Small Cell Lung Cancer. It appears across 6 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-10-31
As disclosedOct 31, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT03178552
PhasePHASE2;PHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorHoffmann-La Roche
Listed asNUVL
Condition(s)Non-Small Cell Lung Cancer
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More NUVL catalysts